The Antidote: Inside the World of New Pharma (73 page)

(
pp. 338
–42) Interviews with Matt Emmens, Ian Smith, Michael Partridge, and Nancy Wysenski. Andrew Pollack, “Vertex Bests Merck in New Hepatitis C Drug Sales,”
New York Times
, October 28, 2011; Adam Feuerstein, “Vertex Earns First Profit, Backed by Blockbuster Pace of Hep C Drug,” TheStreet, October 28, 2011; Luke Timmerman, “Vertex Flips into the Black for First Time, as Hepatitis C Drug Beats Expectations Again,” Xconomy, October 27, 2011.

(
pp. 343
–46) Interviews with Adam Koppel, Michael Partridge, Geoff Porges, Ian Smith, and Bob Beall. Adam Feuerstein, “11 Biotech Stocks Hedge Funds Love and Hate,” TheStreet, August 17, 2011; Marshall Hargrave, “Bain Capital’s Bet Against Romney,”
insidermonkey.com
, October 5, 2012.

(
pp. 346
–49) Interviews with Karolyn Cheng and Bo Cumbo. Liz Highleyman, “AASLD: PSI-7977 Plus Ribavirin Can Cure Hepatitis C in 12 Weeks Without Interferon,”
www.hivandhepatitis.com
, November 8, 2011.

(
pp. 349
–51) Interviews with Ian Smith, Michael Partridge, Nancy Wysenski, Amit Sachdev, and Bob Kauffman. Adam Feuerstein, “Pharmasset Takes Lead in Race to Develop Hep C Therapy by Pill,” TheStreet, November 1, 2011; Luke Timmerman,
“Vertex Stock Drops 17 Percent over Two Days, as Potent Hep C Rivals Emerge,” Xconomy, November 8, 2011; Brett Chase, “Pharmasset Winning Hepatitis C Drug Race,”
Minyanville
, November 7, 2011; Marley Seaman, “Vertex Continues to Slump on Threats to Incivek,”
BloombergBusinessweek
, November 8, 2011.

(
pp. 351
–56) Interviews with Adam Koppel, Geoff Porges, and Matt Emmens.

(
pp. 356
–59) Interviews with Michael Partridge, Bo Cumbo, Ann Kwong, Nancy Wysenski, Ian Smith, Matt Emmens, Josh Boger, and Peter Mueller. Andrew Pollack, “Gilead to Buy Pharmasset for $11 Billion,”
New York Times
, November 21, 2011; Kimberly Ha, Claudia Montato, Yana Morris, and Ashley Armstrong, “Gilead’s ‘Big Bet’ on Pharmasset Hinges on Future Results,”
Financial Times
, November 22, 2011; Bill Berkrot, “Gilead Could Have Had Pharmasset Cheap: Founder,” Reuters, November 22, 2011; Bert Wilkison, “Vertex Trading Near 52-Week Lows After Gilead Acquired Pharmasset,”
Seeking Alpha
, November 22, 2011; Todd Campbell, “Gilead’s Pharmasset Acquisition Makes Vertex Look Cheap,”
Seeking Alpha
, November 22, 2011; Luke Timmerman, “The Hepatitis C Market: Biotech’s Version of the Daytona 500,” Xconomy, December 12, 2011; Robert Weisman, “Jeffrey Leiden Will Head Vertex, Which Gets Priority Review for Cystic Fibrosis Drug Candidate,”
Boston Globe
, December 15, 2011; Ryan McBride, “Interview: Vertex CEO Concerned About Investors’ ‘Hyper-Focus’ on Hep C,”
FierceBiotech
, December 21, 2011; Adam Feuerstein, “The Best Biotech CEO of 2011 Is . . . ,” TheStreet, December 14, 2011.

(
pp. 360
–63) Interviews with Michael Partridge and Eric Olson. Robert Weisman, “In Hepatitis C Market, Vertex Gets a Big New Rival,”
Boston Globe
, January 10, 2012; Luke Timmerman, “Vertex Vows to Fight On with Alios Drugs in High-Stakes Hepatitis C Race,” Xconomy, January 24, 2012; Drew Armstrong, “Vertex Falls as Analyst Cuts Sales Estimates on Hepatitis C Pill,”
Bloomberg
, January 30, 2012; Adam Feuerstein, “Vertex Hep C Sales Growth Nears End,” TheStreet, January 31, 2012; Anna Yukhananov and Bill Berkrot, “FDA Approves Vertex Cystic Fibrosis Drug,” Reuters, January 31, 2012; Robert Weisman, “Vertex Gets Early OK for New Drug,”
Boston Globe
, February 1, 2012; Andrew Pollack, “FDA Approves New Cystic Fibrosis Drug,”
New York Times
, February 1, 2012; Tracy Staton, “Vertex Backs Up Pricey New CF Drug with Co-Pay Help,” FiercePharma, February 1, 2012; Tracy Staton, “How Do the 12 Priciest Drugs in the US Stack Up,” FiercePharma, February 7, 2012; Luke Timmerman, “Vertex’s Big Day Felt Like Moon Landing, Seattle Researcher Says,” Xconomy, February 1, 2012; “In Trial, Hep C Patients Saw Viral Relapse: Gilead,” Reuters, February 17, 2012; Luke Timmerman, “Vertex Stays in HepC Game, as All-Oral Combo Passes Small Study,” Xconomy, February 23, 2012.

(
pp. 363
–64) Interview with Keith Johnson.

(
pp. 364
–65) Interview with Michael Partridge. “A Cystic Fibrosis Treatment Is Called ‘Game-Changing,’ ” Reuters, May 7, 2012; Robert Weisman, “New Data on Cystic Fibrosis Drug Lifts Vertex Stock,”
Boston Globe
, May 8, 2012; Matthew Herper, “A One-Two Punch Against Cystic Fibrosis, and Maybe Someday Other Diseases Too,”
Forbes
, May 7, 2012; “Vertex Pharma Continues to Rise on Upgrade,” Associated Press, May 14, 2012.

(
pp. 365
–67) Interviews and correspondence with Josh Boger. Steven Syre, “Tiny Start-Up Lands a Former Vertex CEO,”
Boston Globe
, May 23, 2012.

(
pp. 367
–71) Interview with Michael Partridge. Meg Tirrell, “Vertex Revises CF Combo Data Showing Less Benefit,” Bloomberg, May 29, 2012; Val Brickates Kennedy, “Analysts Still Upbeat on Vertex,”
Marketwatch.com
, May 29, 2012; Teresa Rivas, “What Next for Vertex?”
Barrons
, May 29, 2012; Robert Weisman, “FDA Says Vertex Promotional Material Overstates Benefits of Hepatitis C Drug,”
Boston Globe
, May 31, 2012; Matthew Herper, “Clearing Up Vertex’s Data Bungle,”
Forbes
, June 1, 2012; Beth Healey, “Two Vertex Executives Are Stepping Down,”
Boston Globe
, June 8, 2012; Ed Silverman, “ The Curious Timing of Those Vertex Stock Sales,”
Forbes
, June 11, 2012; Casey Ross, “Vertex to Fund Partnership with Boston Schools,”
Boston Globe
, June 18, 2012; Luke Timmerman, “After Big Oops, Vertex Plows Ahead with Cystic Fibrosis Drug Combo,” Xconomy, June 28, 2012.